NYSE:EW - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	7,837	2,008	1,757	2,120	23
12/31/2025	7,167	1,852	1,610	1,923	29
12/31/2024	6,562	1,612	1,457	1,838	30
3/31/2024	6,143	1,414	251	528	N/A
12/31/2023	6,005	1,402	630	896	N/A
9/30/2023	5,819	1,431	788	1,042	N/A
6/30/2023	5,657	1,390	682	940	N/A
3/31/2023	5,501	1,489	972	1,239	N/A
12/31/2022	5,382	1,522	953	1,218	N/A
9/30/2022	5,364	1,459	1,040	1,309	N/A
6/30/2022	5,355	1,455	1,261	1,531	N/A
3/31/2022	5,357	1,539	1,428	1,725	N/A
12/31/2021	5,233	1,503	1,402	1,732	N/A
9/30/2021	5,095	1,477	1,409	1,758	N/A
6/30/2021	4,925	1,462	1,050	1,443	N/A
3/31/2021	4,474	851	717	1,148	N/A
12/31/2020	4,386	823	647	1,054	N/A
9/30/2020	4,369	794	692	1,057	N/A
6/30/2020	4,322	744	941	1,279	N/A
3/31/2020	4,484	1,108	1,087	1,389	N/A
12/31/2019	4,348	1,047	905	1,183	N/A
9/30/2019	4,152	774	809	1,073	N/A
6/30/2019	3,964	725	705	978	N/A
3/31/2019	3,821	765	523	777	N/A
12/31/2018	3,723	722	685	927	N/A
9/30/2018	3,634	712	754	998	N/A
6/30/2018	3,549	657	772	966	N/A
3/31/2018	3,447	560	821	1,024	N/A
12/31/2017	3,435	584	N/A	1,001	N/A
9/30/2017	3,315	745	N/A	838	N/A
6/30/2017	3,232	716	N/A	733	N/A
3/31/2017	3,150	657	N/A	726	N/A
12/31/2016	2,964	570	N/A	704	N/A
9/30/2016	2,867	552	N/A	607	N/A
6/30/2016	2,743	528	N/A	604	N/A
3/31/2016	2,601	515	N/A	584	N/A
12/31/2015	2,494	495	N/A	550	N/A
9/30/2015	2,441	463	N/A	539	N/A
6/30/2015	2,433	440	N/A	349	N/A
3/31/2015	2,391	874	N/A	957	N/A
12/31/2014	2,323	811	N/A	1,022	N/A
9/30/2014	2,241	777	N/A	1,040	N/A
6/30/2014	2,129	759	N/A	1,160	N/A
3/31/2014	2,071	306	N/A	511	N/A
12/31/2013	2,046	389	N/A	473	N/A
9/30/2013	2,020	405	N/A	476	N/A
6/30/2013	1,972	398	N/A	475	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EWの予測収益成長率 (年間9.7% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: EWの収益 ( 9.7% ) US市場 ( 14.8% ) よりも低い成長が予測されています。

高成長収益: EWの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: EWの収益 ( 8.6% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: EWの収益 ( 8.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EWの自己資本利益率は、3年後には高くなると予測されています ( 21.6 %)

Edwards Lifesciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Recent updates

Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Corporate VP & CFO notifies of intention to sell stock

Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future

Insider notifies of intention to sell stock

Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability

Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)

Non-Executive Chairman of the Board exercised options and sold US$1.4m worth of stock

When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Announces the Release of Data from the Hudle Study

Now 22% overvalued after recent price rise

Corporate VP & CFO notifies of intention to sell stock

Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear

Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024

Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Non-Executive Chairman of the Board exercised options and sold US$1.5m worth of stock

Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture

Insider notifies of intention to sell stock

Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)

Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024

Non-Executive Chairman of the Board exercised options and sold US$1.5m worth of stock

Investor sentiment improves as stock rises 18%

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024

Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly

The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Corporate VP & CFO notifies of intention to sell stock

Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Non-Executive Chairman of the Board exercised options and sold US$1.1m worth of stock

Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024

Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares.

Insider notifies of intention to sell stock

Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation

Third quarter 2023 earnings: EPS exceeds analyst expectations

Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets

Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Insider exercised options and sold US$214k worth of stock

Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark

Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023

Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Insider notifies of intention to sell stock

A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)

Corporate VP & CFO notifies of intention to sell stock

Edwards Lifesciences: Rising Dominance In Structural Heart Disease

Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry

Non-Executive Chairman of the Board exercised options and sold US$1.3m worth of stock

Insufficient new directors

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023

Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?

Non-Executive Chairman of the Board exercised options and sold US$1.6m worth of stock

Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?

Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value

Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed

Edwards Lifesciences Announces Results of the EU-HYPROTECT Registry

Non-Executive Chairman of the Board notifies of intention to sell stock

Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?